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Abstract
Attention-deficit hyperactivity disorder (ADHD) is one of the most common psychiatric neurodevelopmental disorders
in children and adolescents. Although ADHD has been studied for nearly a century, the cause and pathophysiology of
ADHD is yet largely unknown. However, findings from previous studies have resulted in the formation of a new
hypothesis: Apart from the well-known multifactorial etiology of ADHD, recent evidence suggests that the interaction
between genetic and environmental factors and especially Wnt- and mTOR-signaling pathways might have an
important role in the pathophysiology of ADHD. The Wnt-signaling pathway is known to orchestrate cellular
proliferation, polarity, and differentiation, and the mTOR pathway is involved in several significant processes of
neurodevelopment and synaptic plasticity. As a result, dysregulations of these pathways in a time-dependent manner
could lead to neurodevelopmental delays, resulting in ADHD phenotype. This review presents further evidence
supporting our hypothesis by combining results from studies on ADHD and Wnt- or mTOR-signaling and the influence
of genetics, methylphenidate treatment, Omega-3 supplementation, and stress.
Introduction
Attention-deficit hyperactivity disorder (ADHD) is a
neurodevelopmental disorder characterized by inatten-
tiveness, hyperactivity, and impulsivity1. It is one of the
most common psychiatric and behavioral disorders in
children and adolescents with over 5% of the population
affected worldwide and persists in about 60% of the cases
into adulthood2. ADHD is often accompanied by
comorbidities such as conduct or oppositional defiant
disorder, major depressive disorder (MDD)3, obsessive-
compulsive disorder (OCD)4, personality disorder5, aut-
ism spectrum disorder (ASD)6, and epilepsy7 among
others. Further, ADHD has also been associated with an
increased risk of obesity/overweight8. The burden that
ADHD patients and their families face in daily life greatly
affects their adult life. Moreover, according to a recent
review, the global burden of developmental disorders
including ADHD has not significantly improved since
19909.
Emotional dysregulation has been found also to be very
common in ADHD. It has been suggested to be a sig-
nificant cause of impairment in the different aspects of
ADHD patients’ life10,11. ADHD has also been associated
with polysubstance-dependency, early onset of addiction,
and borderline personality disorder12. A substantial
amount of negative impact on school performance and
long-term academic outcomes has been found in patients
with ADHD. Yet, adequate treatment is able to improve
academic performances13,14. In addition, studies show
that young people with ADHD were at a considerably
higher risk of being involved in accidents15. ADHD
diagnosis, in particular the combined type (hyperactive-
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impulsive subtype), was found to have an impact on
reduced estimated life expectancy16. In addition, in adult
ADHD, the assessed health-related quality of life, work
productivity, and regular daily activities have been found
to be impaired17.
Alterations in brain structure, connectivity, and
maturation processes in patients with ADHD have been
reported18–22. Particularly, a delay in cerebral cortex
maturation predominantly in the frontal cortex has been
noted in ADHD patients18. In a study combining mag-
netic resonance imaging (MRI), diffusion tensor imaging
(DTI), and resting-state functional MRI (fMRI) technique,
alterations were found in the forceps minor, the internal
capsule, the corona radiata, the splenium of the corpus
callosum, and the bilateral basal ganglia of patients with
ADHD23. DTI application revealed that in adults with a
history of ADHD, maturation of white matter was
delayed24. In a recent mega-analysis by the ENIGMA-
ADHD consortium, subtle differences in cortical surface
area were found in children, confirming the involvement
of the frontal cortex in ADHD as well19.
The heritability of ADHD is estimated between 77 and
88%25, however, no single gene alone may predict the
disorder. On the contrary, several studies have indicated
that a third of the heritability in ADHD is caused by the
polygenic component that comprises several common
variants each with small effect size26. Furthermore, a great
deal of evidence supports the interaction between genetic
(polygenic) and environmental factors during early
development, in particular prenatal stress, leading to the
neurobiological susceptibility to the disorder27,28.
Regarding pharmacological treatment, first-line agents
for ADHD are stimulants such as methylphenidate (MPH)
or dexamphetamine29. Structural and functional neuroi-
maging analysis of ADHD brains suggests that psychos-
timulants (e.g., MPH) are associated with normalizing the
aforementioned structural abnormalities seen in ADHD
patients30,31.
Although a wide range of studies has been performed to
understand the underlying pathology of ADHD, the
etiopathology of ADHD is still not fully understood.
Elucidating the etiopathology of ADHD will help to
expand the strategies to reduce symptoms, develop per-
sonalized therapy and predict response to medication
therapy. New insights will additionally reveal potential
biomarkers for improved differential and predictive
diagnosis approaches32. The findings from previous stu-
dies compelled us into forming the following hypothesis:
Apart from the already known multifactorial etiology of
ADHD, recent evidence suggests that the interaction
between genetic and environmental factors and especially
Wnt- and mTOR-signaling pathways might have an
important role in the pathophysiology of ADHD. In this
narrative review of the literature, we will present the
current evidence supporting this hypothesis linking
genetic, stress, and Wnt/mTOR pathways with ADHD, as
well as discuss the missing link that needs to be
investigated.
Biological pathways and their link with ADHD
The Wnt/mTOR pathways
The wingless-INT (Wnt)-signaling pathway is known to
orchestrate cellular proliferation, polarity, and differ-
entiation (Fig. 1); processes that are crucial for healthy
tissue morphogenesis, especially in the embryonic stage33,
but also processes involved in adult neurogenesis34. On
the basis of their activity at the cellular level, Wnt-
signaling has been classified into two categories, canonical
and non-canonical35. In humans, 19 genes were identified
to encode Wnt protein subtypes. Further, they activate
several pathways by coupling with various receptors36. In
the canonical Wnt-signaling pathway, Wnt ligands bind
to a Frizzled (Fzd)/low-density lipoprotein receptor-
related protein (LRP) complex at the cell membrane.
This complex (Wnt/Fzd/LRP) recruits disheveled (Dvl),
which in turn inhibits the pathway, leading to β-catenin
degradation. Once the β-catenin degradation stops, it
accumulates in the cytoplasm before translocating into
the nucleus. Subsequently, there is an interaction between
β-catenin and transcription factor (TCF)/lymphoid-
enhancer factor (LEF) in the nucleus to regulate the
transcription of target genes37. TCF/LEF target genes are
known to regulate stem cell maintenance and differ-
entiation along with cell proliferation38.
The mammalian target of rapamycin (mTOR) pathway
is involved in several significant processes of neurodeve-
lopment and synaptic plasticity (Fig. 1)39. It has also been
described to be associated with neurodevelopmental dis-
orders such as ASD40 and schizophrenia41,42. A compo-
nent of the phosphatidylinositol 3-kinase (PI3K) cell
survival pathway is the mTOR. It has a significant role in
the regulation of cell growth and proliferation. mTOR
operates at a key junction in the PI3K pathway. It further
acts downstream and upstream of protein kinase Akt.
mTOR also regulates the protein synthesis necessary for
proliferation and cell growth by forming two multi-
protein complexes, namely mTOR complex I (mTORC1)
and mTOR complex II (mTORC2)43.
There are three main signaling pathways known to
converge and regulate the mechanistic target of mTOR.
First, the growth factor pathway comprised of PI3Ks,
phosphoinositide-dependent kinase 1 (PDK1), and RAC-
alpha serine/threonine-protein kinase (AKT1). AKT1 is
activated by the phosphorylation of PDK1, which is trig-
gered when PI3K is activated. mTOR is activated via
GTP-binding protein Rheb (RHEB) when tuberous
sclerosis complex (TSC2) gets phosphor-inhibited by
AKT1. This results in the phosphorylation of eukaryotic
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translation initiation factor 4E-binding protein 1 (4E-BP1)
or protein S6 kinase beta-1 (S6K1)44. The second pathway
involves the energy-sensing arm, which responds to low or
insufficient ambient cellular ATP. AMPK is phosphorylated
through the serine/threonine-protein kinase STK11 (also
known as liver kinase B1, LKB1). This results in TSC2-
mediated mTOR inhibition. LKB1 complex activity releases
inhibition of mTOR when the ATP level are abundant45. In
the third pathway, the amino acid sensor GAP activity
toward rags (GATOR1) complex (DEP domain-containing
protein 5, DEPDC5; nitrogen permease regulator proteins
NPRL2 and NPRL3) regulates mTOR in response to
changes in levels of amino acids. In other words, GATOR1
inhibits mTOR-signaling when the level of amino acids are
low. GATOR1 inhibition of mTOR is released once the
amino acid levels return to normal levels46.
Both signaling pathways are not only important for early
normal brain development but also for neurogenesis in
the adult brain47. mTOR has been suggested to regulate
neuronal differentiation and dendritic maturation48.
Canonical Wnt-signaling has a major role in neurogen-
esis. During early neurogenesis, it promotes self-renewal
to maintain neural progenitors. However, during mid and
late neurogenesis it induces the differentiation of pro-
genitor cells34.
Dysregulation of both pathways may lead to pathologi-
cal brain developmental conditions. For example,
Kasherman and colleagues48 have shown how abnormal-
ities in the ubiquitin system, a major regulator of key
signaling cascades including mTOR and Wnt, are linked
to two common neurodevelopmental disorders: intellec-
tual disability (ID) and ASD.
Genetic evidence for Wnt-signaling in ADHD
Although ADHD was found to be highly heritable25,49,
no single genetic variation could be used for diagnosis or
Fig. 1 Current evidence and hypothesis linking elevated stress (cortisol), previous ADHD diagnosis, and methylphenidate (MPH) treatment
or omega-3 PUFA supplementation with the Wnt and mTOR pathways known as key players in cell proliferation, growth, differentiation,
and maturation. The figure was created by BioRender.com. Abbreviations: DEX dexamethasone, GR glucocorticoid receptor, GWAS genome-wide
association study, miRNA non-coding microRNA, MPH methylphenidate, n-3-PUFA Omega-3 long-chain polyunsaturated fatty acids, SNPs single
nucleotide polymorphisms, [number] represent citation in the paper.
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prediction of ADHD. Moreover, the consensus is that
ADHD is considered polygenetic, supporting also the
notion that it is not a clear-cut categorical disorder but
rather the extreme end of the spectrum of a continuous
behavioral trait26. Indeed, the polygenic risk score (PRS)
analysis summarizing statistically all the SNP results from
a large genome-wide association study (GWAS) has
shown some promising results50. For example, ADHD-
PRS was found to associate with symptoms of
hyperactivity-impulsivity and to be mediated by white
matter microstructure in brain regions that have been
suggested to have a role in ADHD pathology51,52. In
addition, ADHD-PRS was found to predict educational
achievement53, to be linked with the severity of the clin-
ical profile in those with high PRS54, and even to predict
MPH response55. Although the etiology and pathways
involved in ADHD cannot be revealed by using PRS only,
this approach seems to be a powerful tool studying
endophenotypes of the heterogeneous disorder.
In the recent Psychiatric Genomic Consortium (PGC)-
ADHD meta-analysis of the GWAS results including over
20,000 cases and 35,000 controls, the first genome-wide
significant loci were identified (12 loci)53. In addition to
the 12 loci that covered 16 genes involved in brain-related
pathways such as synapse formation, neuronal develop-
mental, and dopaminergic transmission, gene set analysis
of the most significant genes revealed that the Wnt/
catenin-signaling pathway is associated with ADHD (gene
ontology biological processes and cellular compart-
ment)53. Further studies on gene variants of the Wnt
pathway were reported in adult ADHD study using
GWAS and extended pedigree linkage56. Here, the
authors reported several genes to be associated with adult
ADHD, as for example, the α-catenin (CTNNA2) which is
known to be involved in Wnt-signaling and to have a role
in the catenin–cadherin cell–adhesion complexes for
synaptic transmission56. Similarly, Aebi and colleagues57,
revealed a significant enrichment of the Wnt/β-catenin
signaling in a subpopulation of ADHD patients with the
oppositional defiant disorder (ODD) by running bioin-
formatics clustering of the GWAS results. In a study
assessing personality disorders, adult ADHD and family-
based childhood ADHD, Kv channel-interacting protein 4
(KCNIP4) gene, suggested to be part of a negative feed-
back loop in the Wnt/β-catenin pathway, was found to
associate with ADHD58.
Interestingly, Rovira and colleagues59 reported recently
a shared contribution of common SNPs in childhood
ADHD and persistent adults in a meta-analysis of data-
bases from large cohorts of ADHD children and persistent
ADHD adults. In this study, the researchers were able to
identify nine loci, containing genes involved in brain
development, associated with ADHD persistence into
adulthood. A significant genetic correlation between
ADHD in childhood and its persistent ADHD in adult-
hood was found, in which also childhood ADHD-PRSs
were associated with persistent ADHD59. Lastly, though
not significant after multiple testing corrections, in the
pathway analysis of persistent ADHD adults, nominal
significant association to the “reactome energy-dependent
regulation of mTOR by LKB1/AMPK”, “biocarta mTOR
pathway”, and “reactome mTORC1-mediated signaling”
was found59.
In a recent study by our group, we found both in family
and case–control samples an association in child and
adolescent ADHD with LRP5 and LRP6 gene variants in
four Caucasian European populations, which was found to
be further significant after meta-analysis with previous
published results60. Additional evidence to the involve-
ment of the Wnt-signaling in ADHD comes from a study
by Wang and colleagues61 who demonstrated in ADHD
patients a significant correlation between low gray matter
volume and three miRNAs (miR-30e-5p, miR-126-5p, and
miR-140-3p) that were found to be involved in the Wnt-
signaling pathways. In a recent study, the genetic archi-
tecture of the human cerebral cortex revealed that com-
mon genetic variants are linked with surface area and
thickness of these regions62. In particular, intriguing is
that loci linked with surface area, which was found to be
negatively correlated genetically with ADHD, clustered
with genes involved in the Wnt-signaling pathways62 (Fig. 1).
Enrichment analysis of transcriptomic (gene expression/
mRNA)63 data sets originating from mouse substantia
nigra64, rat striatum, and frontal cortex65, immortalized
human lymphocytes of adult ADHD and controls66 trea-
ted with MPH resulted in enriched transcripts in Wnt-
signaling pathway. Similarly, in selective breeding for high
home cage activity, the striatum transcriptomic of this
mouse model for ADHD was assessed with and without
amphetamine67. As in the previous models, also high-
active mice enrichment analysis predicted the down-
regulation of the canonical Wnt pathway67.
Indeed, all the above-mentioned results support the
involvement of Wnt-signaling pathways in ADHD and its
phenotypes at the genetic and the transcriptomic level.
Methylphenidate treatment and its link to Wnt/mTOR-
signaling
It is well-known that MPH is one of the first-line drugs
for the treatment of ADHD but despite its relatively high
effect sizes in ADHD children (0.8–1.0 for hyperactivity
and 0.6–0.8 for attention deficit)68, its acute and chronic
effects are still unclear and of continuous concern69,70.
However, no conclusive evidence supporting or dismiss-
ing short- and long-term negative effects of MPH has
been reported up to this date.
In vivo evidences showed that this stimulant affects
positively hippocampal neurogenesis in young rats and
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neuronal plasticity in the amygdala71. Clinical studies using
fMRI analysis report that MPH administration is able to
attenuate ADHD-related impairment in cortical maturation
and functionality in children and adolescents by increasing
gray matter levels in their cortices72–74. Although in gen-
eral, MPH acts as dopamine, norepinephrine, and at low-
level serotonin transporter inhibitor in high-, middle and
low-affinity manners, respectively, thus enhancing the
levels and the biological effects of these monoamines in the
synaptic cleft75, the exact molecular mechanisms (including
the pathways affected by MPH) involved in this context
remains elusive.
In vitro research has revealed that MPH influences cell
proliferation and differentiation, regulating the activity of
synthesizing and metabolizing enzymes responsible for
balancing the monoamine concentration in the cells and the
synaptic cleft76–78, but also acts through a novel mechanism
of action that supports neuronal cell maturation63.
In order to test the influence of MPH on neuronal cell
maturation and its capability of stimulating neurogenesis
and cortical maturation in in vivo models79, our group has
hypothesized that treatment with this drug could lead to
these same effects in neural cell lines through the Wnt-
signaling activation mechanism. This was hypothesized
since it has a pivotal role in maintaining these cellular
processes in several conditions, such as neurogenesis and
differentiation in embryonic development and tissue
homeostasis33,80. More specifically, we were able to
demonstrate in neuronal cell lines (murine stem cells, rat
PC12, and human SH-SY5Y cells) that MPH activates
Wnt-signaling, which was not due to the dopamine
transporter inhibition—the main known therapeutic
mechanism of this drug—since selective dopamine
transporter inhibitor GBR-12909 treatment demonstrated
the opposite effects63. Using a Wnt-luciferase reporter
assay in 3T3 mouse fibroblast cell lines, we could confirm,
quantitatively, that MPH activates the Wnt-signaling63.
In vivo, alterations in the expression of mRNAs involved
in neuronal, synaptic, and axonal processes, in differ-
entiation and in the Wnt-signaling were observed in
MPH-treated rodents64,65. In addition, Oakes and colla-
borators81 found that β-catenin (as well as a vascular
endothelial growth factor—VEGF —and tropomyosin
receptor kinase B—TrkB) levels in juvenile male mice
were elevated after a low dose of chronic MPH treatment
(1 mg/kg) and reduced after high dose chronic treatment
(10 mg/kg) administrated by intraperitoneal injections.
The initial increase in the concentration of these factors
by lower doses was followed by increased proliferation
and survival of hippocampal cells, indicating that they
might act as mediators of these cellular processes81 (Fig. 1).
In 2018, Bae and colleagues82 hypothesized that Wnt-
signaling might also be involved in the pathophysiology of
ASD and that genes belonging to this pathway could be
possible therapeutic targets of drugs shown to be effective
in the therapy of comorbidities in ASD patients, such as
haloperidol and MPH. This hypothesis has arisen based
on the report by Mines and colleagues83, who have found
that an 8-day MPH administration in adult C57Bl/6J mice
was able to regulate phosphorylation of GSK3 and Akt,
which suggests the participation of the drug in this
pathway (Fig. 1). Nevertheless, both drugs have a distinct
mechanism of action, as haloperidol is mainly a dopamine
D2 receptor antagonist used for the treatment of irrit-
ability and aggression in ASD, while MPH is a dopamine
transporter inhibitor used to treat comorbidity of ADHD
in ASD patients.
The concomitant pathway to Wnt, mTOR, was also
implicated in ADHD pathophysiology given that the com-
plex Akt/mTOR-signaling is implicated in cell survival,
synaptic plasticity, and formation, neurogenesis, and
memory consolidation84. Several mutations in participating
proteins on this pathway—for example, TSC1/2, RHEB,
phosphatase tensin homolog (PTEN), and neurofibromin
(NF1)—were described to be implicated with neurological
disorders such as ASD, epilepsy, and ADHD85.
Schmitz and colleagues86 reported that MPH alters the
mTOR pathway at different levels by decreasing the
activity of Akt and mTOR substrates after short term
treatment and increasing them after long-term treatment,
which might regulate the aforementioned neuronal pro-
cesses according to time of treatment (Fig. 1). Based on
the aforementioned data, such evidence supports the
notion of participation of Wnt- and Akt/mTOR-signaling
in ADHD pathophysiology and reinforces the hypothesis
that MPH might directly affect these two key pathways. In
this sense, more studies are required to identify the
molecular mechanisms involved at the cellular level in
order to clarify and elucidate possible therapeutic targets.
Omega-3 fatty acids, ADHD, and Wnt/mTOR-signaling
Omega-3 long-chain polyunsaturated fatty acids (n-3-
PUFA) are essential fatty acids for homeostasis acquired
through diet and include eicosapentaenoic acid (EPA),
alpha-linolenic acid (ALA), and docosahexaenoic acid
(DHA), which are crucial for brain development87,88.
At the molecular level, it is known that n-3-PUFA has
crucial roles in metabolic processes and specific functions
in neural cells such as neurogenesis, neuroinflammation,
and neurotransmission89. In this context, DHA was able to
activate Wnt-signaling in neural cells, promoting upregu-
lation of endogenous Wnt-regulated genes including
PROX1 (an adult neurogenesis marker) and increased cell
survival as well as neurite outgrowth in neurons90. Similarly,
EPA, as well as DHA treatment, promoted differentiation of
induced pluripotent stem cells (iPSC)-derived astrocytes
from MDD patients concomitantly with increased CREB
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activity91, also known to be regulated by the non-canonical
Wnt-signaling.
These compounds were described in a diverse neuro-
logical context such as neuroinflammation. In LPS (lipo-
polysaccharides)-induced neuro-injured mice and PC12
cells, n-3-PUFA treatment increased cellular proliferation
and migration while inhibiting apoptosis92. In addition,
Shi and colleagues92 have reported that these events were
associated with the PI3K-signaling upregulation, which
subsequently led to Akt activation and to an increased
expression of β-catenin. These results point to a possible
simultaneous activation and connection between mTOR-
and Wnt-signaling pathways (Fig. 1).
Another study has also demonstrated that the PI3K/Akt
and mTORC2 pathways were directly related to neuro-
protective effects of n-3-PUFA in vitro. In this study by
Descorbeth and colleagues93, DHA treatment (1–200 µM)
protected Schwann cells from lipotoxicity-mediated cell
death through the activation of the aforementioned
pathways (Fig. 1).
In a whole transcriptomic study of brain hemispheres of
C57BL/6J male mice fed with either standard lab diet (SD)
or with a customized fish oil-enriched diet (FD), genes
involved in cellular growth and proliferation, cellular
development, embryonic development, synaptic trans-
mission, development of the brain, inflammatory
response, and developmental disorders have been found
to differential express following FD94. Interestingly, the
FK506 binding protein 5 (FKBP5) gene, known to be
involved in stress regulation (see details under in chapter
Stress and ADHD), was upregulated following FD point-
ing to the beneficial effects of fish oil supplementation94
(Fig. 1). Moreover, a vast number of genes in the Wnt-
signaling pathway were differentially regulated following
FD supplementation94.
In addition, the nonpharmacological protective
mechanisms of n-3-PUFA have been largely explored in
several neurological diseases95–99. Evidence for alterations
in n-3-PUFA blood levels in ADHD as well as lack of
prenatal n-3-PUFA intake associated with the risk of
ADHD has been reported. In addition, several clinical
trials hint at the improvement of ADHD core symptoms
after add-on n-3-PUFA treatment. Researchers have
recently shown that children with ADHD tend to eat less
Omega-3-enriched food (such as fish and seafood) in
comparison to neurotypical individuals100–102. Indeed,
according to a meta-analysis, child and adolescent ADHD
patients have lower levels of DHA, EPA, and total n-3-
PUFAs compared to controls103. However, the link
between levels of n-3-PUFA and the occurrence of this
disorder in childhood is not limited to postnatal exposure:
Lopez-Vicente and colleagues104 have reported that an
increase in the ratio between n-6 and n-3 concentrations
in cord plasma during pregnancy may increase ADHD
rates when children reach the age of seven. Some inves-
tigations have demonstrated that cognitive functions,
such as working memory, teacher-rated behavior, and
impulsivity, have improved after n-3-PUFA administra-
tion in children with ADHD105–109. In particular, EPA
supplementation seems to elicit small but significant
improvement in inattention and hyperactivity symptoms
in ADHD patients103,110,111. An in vitro study has recently
shown that PC12 dopaminergic cells had their viability
significantly increased after n-3-PUFA administration112,
starting with lower doses (from 100 pM). Interestingly, a
double-blinded report revealed that a combined treatment
of n-3-PUFA plus MPH in a group of ADHD children was
able to increase the efficacy of MPH treatment by sig-
nificantly increasing the response to this drug113. Similarly,
Anand and colleagues114 found that n-3-PUFA could
improve ADHD scores in atomoxetine-treated children in
comparison to the group that received this drug only.
However, the difference was not statistically significant in
cases of inadequate dosage administration114.
In addition, Liu and colleagues97 have described that
PUFA may modulate different signaling pathways in the
brain by increasing the activity of adenylate cyclase and
protein kinase A and thereby influencing serotonin, beta-
adrenergic, and dopamine receptors.
Although, to date, no link was established between n-3-
PUFA, mTOR, and ADHD some evidence has been
reported for n-3-PUFA and mTOR in other neu-
ropsychiatric disorders. Based on mounting evidence
proving that n-3-PUFA have beneficial effects on people
affected by depression, schizophrenia, and bipolar dis-
order115–117 in combination with data on the correlation
between mTOR and other pathologies (e.g., cancer),
Shirooie and colleagues118 reviewed that mTOR can be
one of n-3-PUFA’s targets to treat neurodegenerative
diseases by regulating essential cellular processes such as
apoptosis and autophagy. In addition, Giacobbe and col-
leagues119 have recently discussed the anti-inflammatory
effect of n-3-PUFA within the context of neuropsychiatric
disorders such as depression. This review mentions that
intracerebroventricular injections of resolvins D1, D2, and
E1 (n-3-PUFA metabolites) seem to attenuate depressive-
like behavior in mice via activation of mTORC1-signaling
pathway120,121. Therefore, n-3-PUFA might elicit its
positive effects on ADHD via mTOR, however, this still
needs to be investigated.
To date, there is a lack of evidence connecting Wnt and/
or mTOR pathways, n-3-PUFA supplementation, and the
occurrence of ADHD. Moreover, some results are con-
troversial to the aforementioned positive studies about
favorable aspects of n-3-PUFA supplementation122,123.
Although overall results point to its beneficial effects
mainly in mild ADHD subtypes124, making deeper and
molecular approaches even more necessary.
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Stress and ADHD
As mentioned previously, the susceptibility to ADHD is
influenced by the interaction of polygenic and environ-
mental factors. The impact of environmental risk factors
increases especially during critical developmental stages
in life. The pre- and perinatal periods are associated with
high phenotypic plasticity and thereby represent such
critical developmental episodes125,126. Risk factors such as
maternal life-events such as stress or trauma, alcohol
consumption, and smoking during pregnancy put off-
spring at risk of developing ADHD127–129. However, the
degree to which these are casual effects or due to
unknown confounding factors is highly debated130,131.
Recent studies suggested that risk factors, such as
maternal substance use during pregnancy is associated
with offspring ADHD, are not casual but rather con-
founding by other risk factors132,133.
In terms of maternal influence on ADHD development,
maternal ADHD symptomatology, also in mothers with-
out ADHD diagnosis, may indirectly induce ADHD
symptomatology in the offspring by negatively affecting
the home environment134. Moreover, the presence of
depressive symptoms during pregnancy suggested indu-
cing the early onset of ADHD symptoms in 3- to 6-year-
old children135. Therefore, it is rather difficult to separate
pre, peri-, and postnatal stress effects on the risk of
ADHD, however the overall hypothesis of accumulating
environmental factors including stress may exacerbate it.
In addition, socioeconomic factors seem to be an
essential role in this context, since children whose
mothers are from urban, low-income backgrounds and
had been under psychological stress before and during
pregnancy are more susceptible to develop ADHD136.
Such stress may result directly from maternal cortisol
levels, indirectly from maternal anxiety, depression,
trauma, or even from the administration of synthetic
glucocorticoids such as dexamethasone or betametha-
sone137. Glucocorticoids can influence intracellular sig-
naling pathways as for example the Wnt-signaling
pathways (Fig. 1). An increase in glucocorticoids has been
shown to downregulate both ERK- and PI3K/Akt-signal-
ing pathways138. Treatment of human neural progenitor
cells (hNPCs) with dexamethasone for example increases
the expression of Dickkopf 1 (DKK1) and decreases the
expression of canonical Wnt target genes139. To note, the
Wnt-signaling is important for neurogenesis and its
inhibition causes a defect in neural differentiation and
proliferation, which might explain how stress affects
neurodevelopment80,139. The neuronal and glial ener-
getics hypothesis further describes a possible association
between glucocorticoids and psychiatric neurodevelop-
mental disorders. Glucocorticoids inhibit glycogen
synthesis as well as the supply of glucose to neurons and
astrocytes140. As a result, the glial activity will be
downregulated during stressful situations and will lead to
fatigue and a predisposition for an inefficient and/or
inconsistent behavioral performance140.
It has been confirmed in animal models that ADHD-like
behavioral symptoms and changes in brain function can
result from early life stress141,142. The spontaneous hyper-
tensive rat (SHR) is one of the most extensively studied
animal models for ADHD143. Cognitive performance tests
in SHR indicate an association between cognitive deficits,
insulin resistance, and hypertension144, while Wnt-
signaling has been shown to mediate insulin and blood
pressure regulation and thereby suggests a possible rela-
tionship between Wnt-signaling and ADHD145.
ADHD symptoms are associated with higher perceived
stress146,147. The hypothalamus–pituitary–adrenal axis
(HPA axis) is an important responder to stressful envir-
onments. Several studies have shown that stress reactions
are different in ADHD patients compared to healthy
controls148–151. ADHD patients show reduced diurnal
cortisol levels compared to healthy controls152,153. Corti-
sol levels can be decreased by mineralocorticoids- (MR)
and glucocorticoids- (GR) receptors through a negative
feedback system. GR and MR inhibit the synthesis and
release of corticotropin-releasing factor in the hypotha-
lamus and adrenocorticotrophic hormone in the pituitary
gland154. The candidate gene FKBP5 is involved with the
GR and its pathway155,156. It is an important regulator of
the negative feedback system of the HPA axis by reducing
the sensitivity of GR157. Stress hormones increase the
expression of the FKBP5 resulting in reduced GR affinity
and thereby increase cortisol levels. Polymorphisms on
the FKBP5 gene have been found to be associated with
ADHD156. Moreover, one of the polymorphisms was
found to associate with low cortisol levels and ADHD.
Therefore, FKBP5 might have an important role in linking
Wnt-signaling, stress, and ADHD (Fig. 1).
Preclinical studies158–160 suggest that n-3-PUFAs
improve stress-related neurobiological and behavioral
changes via attenuation of the associated HPA-axis
hyperactivity. The latter findings are suggestive that
dietary n-3-PUFAs may modulate the often observed
HPA-axis dysfunction associated with the development of
some neuropsychiatric disorders including ADHD and
MDD. Observational studies in humans further support a
link between the HPA axis and PUFA metabolism, as
cortisol decreases the production161 and increases the
breakdown of PUFAs162.
Discussion
From the current review of the literature, we suggest the
involvement of Wnt and mTOR pathways in the etio-
pathology of ADHD with a wide range of evidence, at the
genetic, environmental, functional, and molecular as well
as at the pharmacotherapeutic levels. Nevertheless, there
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is still a gap between the current knowledge and the lack
of evidence in neuronal brain tissue originating from
ADHD patients. This, of course, arises because brain tis-
sue is not available since neither biopsies nor post-
mortem samples are available.
Based on the data presented so far, it is noticeable that
genetic factors are relevant in understanding ADHD.
Studying such genetic risk factors at the molecular level is
as important as exploring the environmental factors that
might have a role in the disorder. To illustrate this, we
pointed out the possible involvement of pre-, peri-, and
postnatal stress associated with ADHD also linking it to
the genetic risk factors, possibly together affecting cano-
nical Wnt-signaling, which in turn affects neurodevelop-
ment. Unfortunately, there is still a shortcoming in
understanding the role of stress on the molecular and
cellular levels that needs to be elucidated.
Studying the pathomechanism in human cells is limited
because the relevant tissue, the brain, is not accessible by
biopsy and ADHD post-mortem samples are scarcely
available for research purposes. Although animal models
are a valuable alternative in studying ADHD, they are not
able to mimic the polygenic profile of a patient163.
Therefore, there is an urgent need for a personalized
neuronal model in a dish originating from individuals
with ADHD that maintains their genetic background.
Reprogramming human somatic cells into iPSCs and
differentiating them into neural cells or brain organoids is
a powerful technology that provides the essential means
to study living human central nervous system cells for
modeling complex disorders such as ADHD in a semi
ex vivo manner164. Such personalized models may provide
a platform to test such a hypothesis, enabling the mea-
sures of molecular and functional effects of genetic and
environmental factors on neurodevelopment processes.
In conclusion, both pathways may be associated with
ADHD at the genetic and environmental level linking
both susceptible risk genes with stress. Indeed, Wnt-/
mTOR-signaling and stress were linked with many other
neurodevelopmental and neurodegenerative disorders as
reviewed above. This does not contradict to the fact that
many of these disorders are comorbid as well as share
some phenotypes, e.g., cognition, which might explain the
common mechanisms. However, the polygenic combina-
tion, the time point of alterations, and the time point of
stress might cause to the different trajectories leading to
the disorder, as reviewed by Sullivan and colleagues165.
Following the aforementioned observations, it would be of
utmost importance to test the hypothesis of Wnt- and
mTOR-pathway alterations and stress effects at the cel-
lular level in developing neural cells from ADHD patients
compared to healthy controls. As discussed previously,
the novel technique of using iPSCs to establish a perso-
nalized model of ADHD seems to be a novel platform to
deeply understand the mechanism of ADHD, which will
also provide scope for drug testing. Overall, it would be an
important step forward to form not only effective treat-
ment for ADHD but also for the development of pre-
ventive approaches.
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